Ignite Creation Date:
2024-05-06 @ 4:07 PM
Last Modification Date:
2024-10-26 @ 2:04 PM
Study NCT ID:
NCT04876924
Status:
COMPLETED
Last Update Posted:
2022-03-21
First Post:
2021-05-03
Brief Title:
A Study of BBP-711 ORF-229 in Healthy Adult Volunteers
Sponsor:
Cantero Therapeutics a BridgeBio company
Organization:
Cantero Therapeutics a BridgeBio company
Study Overview
Official Title:
A Phase 1 Randomized Double-Blinded Placebo-controlled Single and Multiple-Ascending Dose Study of the Safety Tolerability Food Effect Pharmacokinetics and Pharmacodynamics of BBP-711 ORF-229 in Healthy Adult Subjects
Status:
COMPLETED
Status Verified Date:
2022-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the safety and tolerability of BBP-711 in healthy adult volunteers
Detailed Description:
This is a single-center two-part randomized double-blinded placebo-controlled ascending dose study of BBP-711 in healthy male and female adult volunteers The purpose of this study is to evaluate the safety and tolerability of BBP-711 in healthy adult volunteers Each volunteer will participate in the study for about 20 days
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None